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Background: The use of laser lead extraction (LLE) to remove pacemaker and implantable cardiac
defibrillator leads has become more prevalent in the past decade. Though the procedure is associated
with a low rate of complications, LLE still poses some risks to patients. Some reports have suggested an
increase in tricuspid insufficiency (TI) associated with LLE. We present a series of patients who underwent
both LLE and complete evaluation for TI with echocardiographic techniques.
Methods: From August 2008 to January 2010, 173 prospective, consecutive patients underwent LLE
in a single center. All patients had transesophageal echocardiograms (TEE) during the extraction. Fifty-
three patients had tricuspid valve function evaluated a day before the procedure with a transthoracic
echocardiogram (TTE), during the procedure with a TEE and 2 days postoperatively with a TTE.
Results: All 173 patients experienced no change in tricuspid valve function during the procedure with
TEE. Of the 53 patients who underwent a complete TI evaluation, 38 were males (72%) and 15 females
(38%), with a mean age of 69.45 ± 14.08. Mean ejection fraction was 35.82 ± 14.72. Three (6%) patients
experienced TI after the procedure (two mild and one severe, all with tricuspid valve endocarditis); 16
(30%) patients were found to have TI before LLE that returned to normal valve function during or after
the procedure. Thirty-four (64%) patients did not experience any significant change of the tricuspid valve
performance after LLE.
Conclusion: LLE was not associated with increased TI. (PACE 2013; 36:939–944)
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Introduction
The role of implantable cardiac devices
continues to increase within medicine. This trend
is reflected both by the prevalence of these devices
in the population and through the fiscal resources
allotted to this area of healthcare. During the
1990s, the number of individuals with pace-
makers (PMs) increased by 22%, whereas those
with implantable cardiac defibrillators (ICDs)
increased 11-fold.1–3 During 2006, an estimated
418,000 pacemaker-related procedures (195,000
PM implantations and 223,000 PM lead-related
procedures) and 114,000 ICD-related procedures
were performed in the United States.3 Regarding
Medicare expenditure data, in the 2009 fiscal
year, an estimated $509,251,000 was spent on
cardiac arrhythmias and conduction disorders.4,5
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As the role for devices continues to broaden, it
will become increasingly important to expand the
literature regarding all aspects of their usage.
The rate of device complications has mirrored
the increase in the prevalence of devices within
our population.6 Because of the fact that these
complications usually necessitate device or lead
removal, several lead extraction methods have
been developed over the past several years—the
most recent method being laser-based techniques.
Laser lead extraction (LLE) has been asso-
ciated with a high rate of procedural success
(96.5%) and a low level of major complications
(1.4%) in the setting of experienced operators in
high-volume centers7; however, some reports have
suggested an increase in tricuspid insufficiency
(TI) associated with LLE.8,9 Our objective is
to report our experience with LLE and the
development of tricuspid regurgitation (TR).
Methods
Patient Population
Data from 173 consecutive patients undergo-
ing LLE at a single high-volume tertiary cardio-
vascular referral center between August 2008 to
January 2010 were obtained from a prospective
registry. All patients had transesophageal echocar-
diograms (TEE) during the extraction. From
this population, 53 patients had tricuspid valve
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function evaluated 1 day before the procedure
with a transthoracic echocardiogram (TTE), during
the procedure with an intraoperative TEE, and
2 days postoperatively with a TTE. The remaining
120 patients did undergo a pre- and postprocedure
TTE; however, the timing of their postprocedure
TTEdid not occur on day 2 (the timing ranged from
day 3 to 8). Informed consent was obtained from
each patient, and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the
institution’s human research committee.
Echocardiograms
Both transthoracic and TEE were interpreted
by a single certified cardiologist echocardiogra-
pher. This echocardiographer was blind to the
study. The severity of the TR was categorized
as trace, mild, moderate, or severe based on
international guidelines.10
Definitions
Extraction was defined in accordance with
the Heart Rhythm Society Expert Consensus
document from 200911: Removal of leads that
have been implanted for more than a year or
leads that required specialized laser equipment.
The indications for transvenous extractions were
also defined by the guidelines; examples were
infection, chronic pain, thrombosis, venous steno-
sis, and functional or nonfunctional leads. The
infection category was further subdivided and
defined: (1) Pocket infection was defined as local
signs of inflammation, device, or lead erosion;
(2) Device endocarditis was defined according
to the modified Duke criteria for endocarditis;
(3) Bacteremia where positive blood cultures were
the only finding. The terms procedural clinical
success, procedure failure, major complications,
and minor complications were taken from the
aforementioned document.
Laser Extraction
Laser sheaths (Spectranetics R©, Colorado
Springs, CO, USA) were used in all the cases by
a single operator. General anesthesia and intra-
operative TEE monitoring were used in all cases.
The incision was performed in the infraclavicular
space. En bloc encapsulectomy was performed
in all the cases. The device was then removed,
and the leads were dissected up to the subclavian
ligament. A lead locking devicewas inserted in the
inner channel of the multifilar coaxial conductor.
Appropriately sized and calibrated laser sheaths
were used under fluoroscopic guidance to release
the binding sites. An outer sheath was used in
approximately 25% of the cases. As the laser
sheath got closer to the myocardial lead tip
interface, counter traction was used to free the
tip of the lead. Throughout this procedure, gentle
tension was maintained to remain coaxial; the
lead was never tugged to reduce trauma to the
tricuspid apparatus. Fluoroscopy was the imaging
modality used to guide the operator; TEE was
used exclusively to evaluate for any complications
during the procedure. When the tricuspid valve
was crossed, laser application was used; there was
no mechanical manipulation. In cases involving
infections, the wounds were closed primarily with
2–0 nylon and subcutaneous drains were used.
This approach was in accordance with Heart
Rhythm Society deemed best practices.
Statistical Analyses
Variable distributions were determined. Con-
tinuous variables were expressed as mean values
and standard deviations. Categorical variables
were expressed as percents. Differences in the pro-
portions involving categorical variables, namely
the severity of TI before and after extraction, were
analyzed using McNemar’s χ2 square test. The
level of significance was set at alpha = 0.05.
All analyses were conducted using IBM SPSS
Statistics v. 18 (IBM Corp., Armonk, NY, USA).
Results
Patient Characteristics
A total of 173 patients underwent device
extraction; from this population, 53 patients
had a complete TI evaluation that included
a preoperative TTE before the procedure, an
intraoperative TEE, and a postoperative TTE 2
days after the procedure. Table I provides a
summary of several descriptive variables; Fig. 1
shows distribution of patient population and
echocardiographic findings.
Indications, Device Properties, and Procedural
Approach
Information regarding the indications for ex-
traction, device characteristics, and lead implant
time are provided in Table II. The most common
indication was infection, and the mean lead
implant time was over 3 years.
Echocardiogram Findings Pre- and
Postprocedure
There were no intraoperative changes in the
severity of TI appreciated via TEE in all 53
patients; however, there were changes appreciated
when the severity of TI was assessed via pre-
and postoperative TTE. The severity of TI was
dichotomized into normal, trace, and mild versus
moderate and severe; the difference in the propor-
tion pre- and postprocedure was compared using
McNemar’s test, and it was found to be statistically
significant (without Yates’ correction P = .003,
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Table I.
Patient Characteristics (n = 53)
Characteristic Value
Age (mean ± SD) 69.45 (SD ± 14.08)
Gender, n (%)
Male 38 (72%)
Female 15 (28%)
Race, n (%)
Caucasian (including Hispanic) 46 (86%)
African American 7 (13%)
Ejection fraction* 35.8 (±14.7)
Comorbid conditions
Hypertension 46 (87%)
Coronary artery disease 37 (69%)
Diabetes mellitus 27 (51%)
Chronic kidney disease 14 (26%)
Hemodialysis 10 (20%)
CHF, n (%) 53 (100%)
NYHA I 22 (42%)
NYHA II 15 (28%)
NYHA III 8 (15%)
NYHA IV 8 (15%)
*Assessed via preoperative transthoracic echocardiogram.
CHF = congestive heart failure; NYHA = New York Heart
Association; SD = standard deviation.
with Yates’ correction P = .008; Table III). Three
(6%) patients experienced worsened or new onset
TI after the procedure—all three of these patients
had tricuspid valve endocarditis with a valvular
vegetation detected by imaging. Sixteen (30%)
patients already displaying different degrees of TI
before the procedure experienced an improvement
in the severity of TI via postprocedure TTE.
Thirty-four (64%) patients did not experience
any significant change of the tricuspid valve
performance after LLE.
Of note, from the 120 patients who did not
meet inclusion criteria (because of the fact that
their pre- and post-TTEs did not occur on the
defined time period), there was no change in
their TR severity during the procedure via TEE.
There was a significant difference in TR severity
in their pre- and post-TTEs. From this group,
66 patients had normal/trace/mild TR before the
procedure and 85 after the procedure; 54 patients
had moderate/severe TR before the procedure and
35 after (McNemar’s P < 0.01).
Intraoperative Transesophageal
Echocardiography
None of the 173 patients from the prospective
registry were observed to have worsening TI via
intraoperative TEE (Fig. 1).
Discussion
Our findings demonstrate that there was no
evidence of an increase in the severity of TI using
intraoperative TEE; however, there were signifi-
cant changes appreciated when the severity of TI
was assessed via pre- and postoperative TTE. This
discrepancy may be explained by confounding
variables such as the imaging modality used to
assess TR, the presence of valvular involvement
in an implantable cardiac device infection, and
the patient’s fluid status (particularly patients
with end-stage renal disease on hemodialysis),
among other factors. The method of extraction
may greatly influence the development of post-
extraction TI; the fact that our study used solely
LLE to reduce themagnitude of force applied to the
tricuspid apparatus likely explains our different
experience compared to current literature. In
addition, the importance of recognizing tricuspid
valve involvement during cardiac device infective
endocarditis (CDIE) is imperative given that it
portends a worse prognosis.
In our study, we utilized both TTE and
TEE. With respect to assessing the severity of
TI, both methodologies are comparable, given
the fact that even when parasternal and apical
views are suboptimal using a TTE, subcostal views
allow color flowmapping and recording of hepatic
vein pattern.10 The main utility in using TEE
in our study is that it allowed us to monitor
for changes in valvular function intraoperatively
in addition to the fact that it may increase the
sensitivity for detecting valvular vegetations.12
In all 173 cases, including the 53 patients who
underwent a complete TI evaluation, there were
no changes in the severity of TR appreciated
intraoperatively. From the 53 patients, 16 were
noted to have an improvement and three had
worsening valvular functioning via TTE. This
discrepancy between TTE and TEEmay be a reflec-
tion of confounding variables in the perioperative
period. Ten of the 16 patients who demonstrated
an improvement in valvular function underwent
dialysis immediately following the procedure.
Moreover, all three patients who experienced
an increase in TR had evidence of tricuspid
valve involvement (vegetations) in conjunction
with CDIE. Of note, the three patients with
endocarditis had newly implanted leads. The
mechanism behind why these patients experi-
enced worsening TR following the procedure is
unclear.
Our study used solely laser sheath extraction
to remove device leads; we did not attempt
simple traction nor did we employ any other
lead extraction technique. The original PLEXES
(Pacing Lead Extraction With the Excimer Sheath)
trial, a randomized prospective clinical trial,
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Figure 1. Distribution of patient population and echocardiographic findings. TEE = trans-
esophageal echocardiogram; TTE = transthoracic echocardiogram.
compared a laser sheath to a nonlaser cohort in
301 patients. The procedural success rate and
major complication rate in the laser cohort were
94% and 1.96%, respectively, whereas the success
rate for the nonlaser cohort was 64%, often
requiring crossover to laser sheath extraction.13
The major reason between this difference in
procedural success rate may be a function of
the fibrotic attachments that gradually encompass
the lead. These fibrotic attachments have been
described involving the tricuspid valve apparatus
and ventricular device leads.14,15 Telescoping
stainless steel and polymer sheaths require
mechanical force to pass them over the leads
through dense fibrous tissue, whereas the laser
sheath emits pulsed ultraviolet light that ablates
the tissue.13 Based on the laser sheath’s method
of action, it likely reduces the magnitude of force
applied to the tricuspid apparatus. Our study is
the first to assess TI following lead extraction that
uses solely LLE in every case without any other
technique. This may likely explain the different
results that we obtained compared to the current
literature. We used gentle tension to stay coxial
during the extraction, to further prevent any injury
to the SVC. Our complication rate was 1.2%, and
we did not experience any injury to the superior
vena cava. Our complication rate is in line with
the Lexicon study, which was 1.4%.7
Other studies have analyzed the use of laser
sheath lead extraction and the development of
TR. In a study performed by Franceschi et al.,
237 ventricular leads were removed from 208
patients.8 The method their group employed for
lead extraction was first simple traction or, if the
lead had been implanted for more than 6 months,
traction after introducing a locking stylet into the
lead lumen. Onlywhen removal by simple traction
was not successful they employed either laser
sheath or lasso (the choice between these two
was left to the operator). All patients underwent
a preoperative and a postoperative TTE to assess
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Table II.
Indications, Device Properties, and Procedural Approach
(n = 53)
Indications, n (%)
Infection 41 (78)
Malfunction 12 (22)
Devices, n (%)
PM 20 (38)
ICD 24 (45)
CRT-ICD 9 (17)
Leads, n (%)
Total 111
Atrial 40 (37)
Ventricular* 60 (54)
Coronary sinus 11 (10)
Lead time (mo.) 38.4 ± 42.8
Approach, n (%)
Subclavian 111 (100)
Total procedure time 146 ± 23 minutes
Fluoroscopy Time 38 ± 11 minutes
Size of sheath used
12 Fr 6 (11)
14 Fr 43 (81)
16 Fr 4 (8)
CRTICD = cardiac resynchronization therapy implantable cardiac
defibrillator; ICD = implantable cardiac defibrillator; PM =
pacemaker.
for TR. In their experience, use of laser sheath for
lead removal, after failure of simple traction, was
the single most powerful risk factor for traumatic
tricuspid regurgitation (TTR). The authors stated
that the role of laser sheath in the occurrence
of TTR was difficult to assess in their study
because that modality was reserved for difficult
extractions.7
Evidence of tricuspid involvement during
CDIE portends a worse prognosis when compared
to CDIE alone. A recent study by Athan et al.,
a prospective multicenter study, enrolled 2,760
patients with infective endocarditis.16 From this
population, 177 were found to have CDIE. Their
group compared mortality at 1 month and at
1 year between a cohort with CDIE and no
evidence of valvular involvement and a cohort
with CDIE and evidence of valvular involvement;
of note, tricuspid valve involvement accounted
for 65% of all cases of CDIE with concomitant
valvular involvement in their study. The differ-
ence inmortality at 1 month for the cohort without
evidence of lead vegetation and that with evidence
was 79% and 62%, respectively; the difference in
mortality at 1 year for the same cohorts was 50%
and 30%, respectively.16 These results emphasize
the importance of prompt management following
the guidelines established by Baddour et al., em-
phasizing device explantation and the appropriate
use of antibiotics. Moreover,17 the results also
encourage health practitioners to further stratify
patients with CDIE into subgroups, particularly
thosewith evidence of valve involvement, because
their prognosis is often worse.
Study Limitations
The study population consisted of 53 patients;
the sample size was limited and originated from
a single tertiary referral center and a single
operatorwas used. A large population from several
facilities in addition to several operators could
be used to increase the generalizability of the
findings. In addition, the average lead time in this
study was approximately 38 months. A cohort
with a greater lead time should be assessed in
future studies. Of note regarding our cohort of
patients, the patients with structural damage to
Table III.
Echocardiogram Findings Pre- and Postprocedure (n = 53)
Preoperative Postoperative
Echocardiogram Echocardiogram P
Tricuspid insufficiency, n (%)
Normal 10 (19) 20 (38)
Trace 8 (15) 9 (17)
Mild 13 (25) 11 (21)
Moderate 16 (30) 8 (15)
Severe 6 (11) 5 (9)
Normal/trace/mild 31 (58) 40 (75) .003*
Moderate/severe 22 (42) 13 (25)
*The P value is derived using an uncorrected McNemar χ2 square. The P value corrected for continuity (Yates) is 0.008.
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the tricuspid valve that were symptomatic and
refractory to medical management were managed
surgically as they were initially referred directly
for surgical evaluation. The patients who had
severe TR and structural damage that were
managed medically were referred to our facility
for lead extraction.
Conclusion
LLE was not associated with increased TI.
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